clinical trial · NCT04664738
PEP on a Skin Graft Donor Site Wound
Skin Graft10% PEPTISSEEL20% PEP
brief summary
The purpose of this study is to determine the safety of a biological therapeutic PEP in participants who have skin graft donor site wounds.
started
Mar 16, 2021
primary completion
Aug 9, 2023
completion
Feb 2, 2024
last updated
Sep 8, 2023
detailed description
This is an open label phase 1b study of PEP (a leukocyte depleted blood preparation derived from human U.S. sourced pooled apheresed platelets) in patients with at least two donor split-thickness skin graft wounds. One donor site will be treated with the standard post-operative dressing, while the other site will be treated with PEP or PEP+TISSEEL and covered with a standard dressing. TISSEEL is a commercially available fibrin sealant.
official title
A Phase I Open-Label Trial to Determine the Safety of PEP on a Skin Graft Donor Site Wound
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol